相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age
Monika Engelhardt et al.
HAEMATOLOGICA (2020)
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
Christine Greil et al.
HAEMATOLOGICA (2019)
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
Francesca Gay et al.
HAEMATOLOGICA (2018)
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
Francesca Gay et al.
HAEMATOLOGICA (2018)
Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response
Nicola Lehners et al.
CANCER MEDICINE (2018)
Current Developments in Immunotherapy in the Treatment of Multiple Myeloma
Martin Koehler et al.
CANCER (2018)
Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)
Johannes M. Waldschmidt et al.
HAEMATOLOGICA (2018)
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
Alessandra Larocca et al.
LEUKEMIA (2018)
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig et al.
LEUKEMIA (2018)
Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials*
Laura Gengenbach et al.
LEUKEMIA & LYMPHOMA (2018)
Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)
Johannes M. Waldschmidt et al.
HAEMATOLOGICA (2018)
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers et al.
HAEMATOLOGICA (2018)
Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation
M. van Gelder et al.
BONE MARROW TRANSPLANTATION (2017)
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
Monika Engelhardt et al.
HAEMATOLOGICA (2017)
Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study
Lasse Hjort Jakobsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
Monika Engelhardt et al.
HAEMATOLOGICA (2017)
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Knut B. Smeland et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?
Monika Engelhardt et al.
HAEMATOLOGICA (2016)
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
Monika Engelhardt et al.
HAEMATOLOGICA (2016)
Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?
Monika Engelhardt et al.
HAEMATOLOGICA (2016)
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
Monika Engelhardt et al.
HAEMATOLOGICA (2016)
Conditional Melanoma Cancer Survival in the United States
Ray M. Merrill et al.
CANCERS (2016)
Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time
Stefanie Hieke et al.
CLINICAL CANCER RESEARCH (2015)
Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years
Monika Engelhardt et al.
HAEMATOLOGICA (2015)
Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006
Dai Chihara et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years
Monika Engelhardt et al.
HAEMATOLOGICA (2015)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
Conditional survival of malignant melanoma in The Netherlands: 1994-2008
Robert J. T. van der Leest et al.
EUROPEAN JOURNAL OF CANCER (2014)
Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands
Saskia A. M. van de Schans et al.
HAEMATOLOGICA (2014)
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Monika Engelhardt et al.
HAEMATOLOGICA (2014)
The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy
Naohiro Sekiguchi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Matthew J. Maurer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
P. Leif Bergsagel et al.
BLOOD (2013)
Conditional survival for longer-term survivors from 2000-2004 using population-based cancer registry data in Osaka, Japan
Yuri Ito et al.
BMC CANCER (2013)
Validation of the Freiburg Comorbidity Index in 466 Multiple Myeloma Patients and Combination With the International Staging System Are Highly Predictive for Outcome
Martina Kleber et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
An Individualized Conditional Survival Calculator for Patients with Rectal Cancer
Tawnya L. Bowles et al.
DISEASES OF THE COLON & RECTUM (2013)
Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies
A. M. VanderWalde et al.
LEUKEMIA (2013)
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
H. Avet-Loiseau et al.
LEUKEMIA (2013)
Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis
Marcus C. B. Tan et al.
HPB (2013)
Clinical Calculator of Conditional Survival Estimates for Resected and Unresected Survivors of Pancreatic Cancer
Matthew H. G. Katz et al.
ARCHIVES OF SURGERY (2012)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry
Massimo Offidani et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
Fiona M. Ross et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Conditional Probability of Survival in Patients With Newly Diagnosed Glioblastoma
Mei-Yin C. Polley et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects
Peter D. Baade et al.
MEDICAL JOURNAL OF AUSTRALIA (2011)
Conditional Survival and the Choice of Conditioning Set for Patients With Colon Cancer: An Analysis of NSABP Trials C-03 Through C-07
Beth A. Zamboni et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical Relevance of Conditional Survival of Cancer Patients in Europe: Age-Specific Analyses of 13 Cancers
Maryska L. G. Janssen-Heijnen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model
Xu Zhang et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in southwest oncology group chemotherapy trials
BGM Durie et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol
A Riccardi et al.
EUROPEAN JOURNAL OF CANCER (2003)
分享论文
